Autolus Therapeutics plc (AUTL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Autolus Therapeutics plc (AUTL) closed at USD 1.69 on 2026-10-14, a change of +9.7 % over the past year, with a market capitalization of USD 457.8M.

Autolus Therapeutics plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Autolus Therapeutics plc key figures

Previous close

USD 1.69 (2026-10-14)

1-year change

+9.7 %

Market cap

USD 457.8M

Enterprise value

USD 623.98M

P/E ratio (trailing)

-1.55

P/E ratio (forward)

-2.70

EPS (trailing)

-1.11

EPS (forward)

-0.64

PEG ratio

n/a

Price to book

6.12

Revenue growth

118.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.29

Employees

752

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Autolus Therapeutics plc and compare it with other stocks.